Adaptive Biotechnologies Q4 2021 Earnings Report

Adaptive Biotechnologies reported a revenue increase of 26% year over year, driven by growth in sequencing revenue.

Key Takeaways

Adaptive Biotechnologies reported a strong finish to the year with a 26% increase in revenue compared to the fourth quarter of the prior year. The growth was driven by both sequencing and development revenue categories. The company recognized $10.0 million in MRD regulatory milestones.

Revenue of $37.9 million, representing a 26% increase year over year.

clonoSEQ clinical sequencing volume increased 41% to 6,356 clinical tests.

Recognized $10.0 million in MRD regulatory milestones.

Received Emergency Use Authorization (EUA) from FDA for T-Detect™ COVID.

Total Revenue

$37.9M

Previous year: $30.2M

+25.7%

EPS

-$0.43

Previous year: -$0.33

+30.3%